Patents by Inventor Paulette LEGENDRE

Paulette LEGENDRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies for the prevention or the treatment of bleeding episodes
    Patent number: 11597777
    Abstract: The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: March 7, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDECALE), UNIVERSITE PARIS—SUD, CENTRE HOSPITALIER REGIONALE UNIVERSITAIRE DE LILLE, UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2
    Inventors: Petrus Lenting, Cécile Denis, Olivier Christophe, Paulette Legendre, Antoine Rauch, Sophie Susen
  • ANTIBODIES FOR THE PREVENTION OR THE TREATMENT OF BLEEDING EPISODES
    Publication number: 20200095335
    Abstract: The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).
    Type: Application
    Filed: December 10, 2019
    Publication date: March 26, 2020
    Inventors: Petrus LENTING, Cécile DENIS, Olivier CHRISTOPHE, Paulette LEGENDRE, Antoine RAUCH, Sophie SUSEN
  • Antibodies for the prevention or the treatment of bleeding episodes
    Patent number: 10544231
    Abstract: The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 28, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE PARIS—SUD, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE, UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2
    Inventors: Petrus Lenting, Cécile Denis, Olivier Christophe, Paulette Legendre, Antoine Rauch, Sophie Susen
  • ANTIBODIES FOR THE PREVENTION OR THE TREATMENT OF BLEEDING EPISODES
    Publication number: 20170037148
    Abstract: The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13 -mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).
    Type: Application
    Filed: April 16, 2015
    Publication date: February 9, 2017
    Inventors: Petrus LENTING, Cécile DENIS, Olivier CHRISTOPHE, Paulette LEGENDRE, Antoine RAUCH, Sophie SUSEN